225 results on '"Gaggar, Anuj"'
Search Results
2. COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation
3. Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection
4. Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells
5. Compassionate Use of Remdesivir for Patients with Severe Covid-19
6. Targeted long-read sequencing reveals clonally expanded HBV-associated chromosomal translocations in patients with chronic hepatitis B
7. Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response
8. Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection
9. An OX40/OX40L interaction directs successful immunity to hepatitis B virus
10. Longitudinal liver sampling in patients with chronic hepatitis B starting antiviral therapy reveals hepatotoxic [CD8.sup.+] T cells
11. Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection
12. Ledipasvir-sofosbuvir in Adolescents With Chronic Hepatitis C and Hematological Malignancies Undergoing Chemotherapy
13. Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection
14. Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
15. TLR7 Agonist Increases Responses of Hepatitis B Virus–Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues
16. Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B
17. Complex genetic encoding of the hepatitis B virus on-drug persistence
18. Chemical Transformations in Individual Ultrasmall Biomimetic Containers
19. P1- HIGH VIRAL SUPPRESSION AND IMPROVED SAFETY PROFILE OF TENOFOVIR ALAFENAMIDE RELATIVE TO TENOFOVIR DISOPROXIL FUMARATE IN CHRONIC HEPATITIS B PATIENTS TREATED FOR 5 YEARS
20. Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients
21. Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells
22. Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg ‐positive chronic hepatitis B
23. Chronic hepatitis C virus infection in India: Regional demographics and distribution of viral genotypes
24. Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations With Implications on Host Gene Dysregulation
25. Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg‐positive chronic hepatitis B.
26. Sofosbuvir and risk of estimated glomerular filtration rate decline or end‐stage renal disease in patients with renal impairment
27. Risk of hepatocellular carcinoma in treatment‐naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States
28. Exhausting the Differential
29. Antiviral kinetics of tenofovir alafenamide and tenofovir disoproxil fumarate over 24 weeks in women of childbearing potential with chronic HBV
30. 3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China
31. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19
32. Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis
33. Remdesivir for 5 or 10 Days in Patients With Severe Covid-19
34. Age-dependent hepatic lymphoid organization directs immune priming, cytokine production, and successful immunity to Hepatitis B virus: S-3
35. CD46 is a cellular receptor for group B adenoviruses
36. Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study
37. Sa1525 SAFETY AND EFFICACY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: WEEK 24 RESULTS FROM A PHASE 2 OPEN-LABEL STUDY
38. Sa1522 EFFICACY AND SAFETY OF SWITCHING TO TENOFOVIR ALAFENAMIDE IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B PATIENTS WITH RENAL IMPAIRMENT: WEEK 24 RESULTS FROM A PHASE 2 OPEN-LABEL STUDY
39. Durability of Hepatitis B Surface Antigen Loss With Nucleotide Analogue and Peginterferon Therapy in Patients With Chronic Hepatitis B
40. RETRACTION: Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients with Chronic HBV Infection
41. Genomic modeling of hepatitis B virus integration frequency in the human genome
42. Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis
43. 405 – Efficacy and Safety Results 48 Weeks After Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) Vs Continued Tdf Treatment in Virologically-Suppressed Patients with Chronic Hepatitis B (CHB)
44. 953 – High Efficacy and Improvement in Cpt Class with Sofosbuvir/Velpatasvir Plus Ribavirin for 12 Weeks in Patients with Cpt C Decompensated Cirrhosis
45. Tu1501 – Ledipasvir/Sofosbuvir for 8, 12, Or 24 Weeks is Safe and Effective in Patients Undergoing Dialysis
46. 406 – Chronic Hbv Patients Who Switched to Tenofovir Alafenamide (TAF) After Either 2 Or 3 Years of Prior Tenofovir Disoproxil Fumarate (TDF) Treatment Demonstrated Improvement in Bone and Renal Safety
47. Tu1502 – Ledipasvir/Sofosbuvir is Highly Effective and Safe in Patients with Chronic Hepatitis B Virus and Hepatitis C Virus Coinfection: Final Study Results
48. 954 – Chronic Hepatitis C (CHC) Patients Who Do Not Achieve Sustained Virologic Response (SVR) Experience Worsening of Their Health-Related Quality of Life (HRQL)
49. J-104 Towards a functional cure for HBV: An industry perspective
50. Gene expression profiling of human tissue-resident immune cells: Comparing blood and liver
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.